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Abstract
Background: Knowledge of the molecular basis and transport function of the human blood–brain barrier (BBB) is
important for not only understanding human cerebral physiology, but also development of new central nervous
system (CNS)-acting drugs. However, few studies have been done using human brain capillary endothelial cells,
because human brain materials are difficult to obtain. The purpose of this study is to clarify the functional
expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line
hCMEC/D3, which has been recently developed as an in vitro human BBB model.
Methods: Diphenhydramine, [3H]pyrilamine and oxycodone were used as cationic drugs that proved to be H+/OC
antiporter substrates. The in vitro uptake experiments by hCMEC/D3 cells were carried out under several conditions.
Results: Diphenhydramine and [3H]pyrilamine were both transported into hCMEC/D3 cells in a time- and
concentration-dependent manner with Km values of 59 μM and 19 μM, respectively. Each inhibited uptake of the
other in a competitive manner, suggesting that a common mechanism is involved in their transport. The
diphenhydramine uptake was significantly inhibited by amantadine and quinidine, but not tetraethylammonium
and 1-methyl-4-phenylpyridinium (substrates for well-known organic cation transporters). The uptake was inhibited
by metabolic inhibitors, but was insensitive to extracellular sodium and membrane potential. Further, the uptake
was increased by extracellular alkalization and intracellular acidification. These transport properties are completely
consistent with those of previously characterized H+/OC antiporter in rat BBB.
Conclusions: The present results suggest that H+/OC antiporter is functionally expressed in hCMEC/D3 cells.
Keywords: Human blood–brain barrier, Human BBB model cell, hCMEC/D3 cells, Proton-coupled organic cation
antiporter, Organic cation transporter, Transport function, Diphenhydramine, Pyrilamine, Oxycodone, Active
transport, Real-time PCR
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Background
The human brain is protected by the existence of the
blood–brain barrier (BBB), which consists of brain capil-
lary endothelial cells linked with tight junctions [1]. It is
well established that the polarized expression of numer-
ous transporters and receptors at the brain capillary
endothelial cells controls the blood–brain exchange of
nutrients, waste products produced from neurotransmit-
ter substances, and drugs [2]. Therefore, knowledge of the
molecular basis and transport function of the human BBB
is important for not only understanding human cerebral
physiology, but also for development of new central ner-
vous system (CNS)-acting drugs. However, few studies
have been done using human brain capillary endothelial
cells, because human brain materials are difficult to ob-
tain. In addition, isolation and primary culture of brain ca-
pillary endothelial cells are laborious and time-consuming
procedures [3,4]. Therefore, the development of simple
in vitro BBB models is highly desirable.
Human immortalized brain capillary endothelial cells
(hCMEC/D3) have recently been developed as an in vitro
human BBB model [5]. This cell line has been now exten-
sively validated by numerous laboratories worldwide in
pharmacological, toxicological, immunological and infec-
tion studies. These hCMEC/D3 cells retain many of the
morphological and functional characteristics of the human
BBB in terms of expression of multiple transporters, recep-
tors, tight junction proteins and various ABC transporters,
including ABCB1 (MDR1/P-gp), ABCC1 (MRP1), ABCC4
(MRP4), ABCC5 (MRP5), and ABCG2 (BCRP) [2,6,7]. Fur-
thermore, several solute carrier (SLC) transporters respon-
sible for the blood–brain exchange of mainly nutrients,
including SLC2A1 (GLUT1), SLC16A1 (MCT1), SLC29A1
(ENT1) and so on, are highly expressed at the mRNA level
in this cell line [8]. On the other hand, little is known
concerning the expression and function of influx transpor-
ters that may regulate the brain distribution of drugs,
except for relatively abundant expression of SLCO2A1
(OATP2A1) at the mRNA level [8].
Recently, we have reported that a H+/OC antiporter is
functionally expressed in the in vivo rat BBB and also in
a conditionally immortalized rat BBB cell line (TR-BBB13
cells) [9,10]. This H+/OC antiporter mediates blood–brain
transport of CNS-acting cationic drugs such as pramipex-
ole, oxycodone and diphenhydramine, in addition to pyrila-
mine, in rats. A brain microdialysis study revealed that this
transporter actively transports oxycodone and diphen-
hydramine into the brain, and their unbound concentration
in brain interstitial fluid (ISF) is 3- to 5-fold higher than
that in blood [10,11]. There is also evidence that clonidine
[12] and methylenedioxymethamphetamine (MDMA) [13]
are transported by H+/OC antiporter in the BBB and in
peripheral cell lines, respectively. Although the molecular
entity of this transporter remains unknown, the known
substrates are secondary or tertiary amines with positive
charge at physiological pH. This suggests that many CNS
drugs used in the clinical setting may be efficiently taken
up into the brain via the H+/OC antiporter at the BBB. In
addition, this putative transporter is a potential target in the
development of new CNS drugs.
The purpose of this study, therefore, is to clarify
the functional expression of the H+/OC antiporter in
hCMEC/D3 cells. We also discuss whether or not the
results of in vitro uptake study using hCMEC/D3 cells
can be extrapolated to the human BBB in vivo, as well
as the relevance of our findings to cerebral physiology
and to the development and proper use of CNS-acting
cationic drugs.
Methods
Reagents
Diphenhydramine hydrochloride was purchased from
Wako Pure Chemical Industries (Osaka, Japan), [3H]Pyrila-
mine (23 – 30 Ci/mmol) and [14C]inulin (2.06 mCi/g) were
purchased from Amersham Bioscience (Buckingshamshire,
UK) and PerkinElmer Life and Analytical Sciences, Inc.
(Walthan, Massachusetts, USA), respectively. Oxycodone
was kindly provided by Takeda Pharmaceutical Co. Ltd.
(Osaka, Japan). All other chemicals and reagents, in-
cluding diphenhydramine, were commercial products of
reagent grade.
Cell culture
The hCMEC/D3 cells had been immortalized by lentiviral
transduction of the catalytic subunit of human telomerase
and SV40-T antigen [5]. The cells were cultivated at 37°C
in EBM-2 medium (Takara Bio, Shiga, Japan) supplemen-
ted with 2.5% fetal bovine serum, 0.025% VEGF, 0.025%
R3-IGF, 0.025% hEGF, 0.01% hydrocortisone, 5 μg/mL
bFGF, 1% penicillin-streptomycin and 10 mM HEPES on
rat collagen type I coated dishes in 95% air and 5% CO2.
Animals
Adult male Wistar rats weighing about 350 g were pur-
chased from Japan SLC (Shizuoka, Japan); they were
housed, three or four per cage, in a laboratory with free
access to food and water and were maintained on a
12-hr dark/12-hr light cycle in a room with controlled
temperature (24 ± 2°C) and humidity (55 ± 5%). This
study was conducted according to guidelines approved
by the Experimental Animal Ethical Committee of
Teikyo University.
Transport studies
The hCMEC/D3 cells used for the experiments were be-
tween passage 25 and 35. The cells were seeded on rat
collagen I-coated multi-well plates (Becton Dickinson) at
a density of 0.2 × 105 cells/cm2. At 3 days after seeding
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the cells reached confluence, the cells were washed twice
with 2 mL of phosphate-buffered saline (pH 7.4) and
preincubated with the transport buffer (122 mM NaCl, 3
mM KCl, 25 mM NaHCO3, 1.2 mM MgSO4, 1.4 mM
CaCl2, 10 mM D-glucose, 10 mM HEPES, pH 7.4) for 20
min at 37°C. After preincubation, 1 mL of the transport
buffer containing diphenhydramine (30 μM) or [3H]pyri-
lamine (74 kBq/μL, 90 nM) was added to initiate uptake.
The cells were incubated at 37°C for a designated time,
and then washed three times with 2 mL of ice-cold incu-
bation buffer to terminate the uptake. In the case of di-
phenhydramine, the cells were collected in 400 μL of
0.5% KH2PO4 solution, and stored at −20°C until HPLC
determination as described below. For the determination
of [3H]pyrilamine radioactivity, the cells were solubilized
with 1 M NaOH for 60 min and the radioactivity was
measured using a liquid scintillation counter after the
addition of scintillation cocktail Hionic Fluor (PerkinElmer
Life and Analytical Sciences). Cellular protein content was
determined with a BCA protein assay kit (Pierce Chemical
Co., Rochford, IL, USA).
Uptake was expressed as the cell-to-medium ratio (μL/
mg protein) obtained by dividing the uptake amount by
the concentration of substrate in the transport buffer. In
order to estimate transporter-mediated specific uptake
parameters in the kinetic analyses, the cell-to-medium
ratios for saturable components of diphenhydramine (30 –
500 μM, for 15 sec) and [3H]pyrilamine (6 – 500 μM, for
10 sec) were determined by subtracting the cell-to-medium
ratios at the concentration of 5 mM diphenhydramine and
5 mM pyrilamine, respectively. The non-saturable uptake
component can be estimated from the uptake in the pres-
ence of an excess of substrate. The initial uptake rates for
saturable components were determined by multiplying the
cell-to-medium ratios for saturable component by the sub-
strate concentration in the transport buffer [9,10]. The data
were fitted to the following equation to estimate the kinetic
parameters by means of nonlinear least-squares regression
analysis with Prism software (Graphpad, San Diego, CA,
USA):
V ¼
Vmax  s
Km þ s
where V is the initial uptake rate of substrate (nmol/min/
mg protein), s is the substrate concentration in the medium
(μM), Km is the Michaelis-Menten constant (μM) and Vmax
is the maximum uptake rate (nmol/min/mg protein). Vmax/
Km (pmol/min/mg protein/μM = μL/min/mg protein)
values were calculated as the uptake clearance for the satur-
able transport component.
In order to examine the energy dependency of diphen-
hydramine uptake by hCMEC/D3 cells, the uptake was
measured as described above after pretreatment with
25 μM rotenone (dissolved in the transport medium
containing 0.25% ethanol) or 0.1% NaN3 for 20 min. In this
experiment, 10 mM D-glucose in the transport medium
was replaced with 10 mM 3-O-methylglucose to reduce
metabolic energy. In order to examine the sodium require-
ment of diphenhydramine uptake by hCMEC/D3 cells,
sodium ions were replaced with N-methylglucamine+. To
examine the effects of reducing the membrane potential
and proton gradient on diphenhydramine uptake by
hCMEC/D3 cells, 10 mM valinomycin and 10 μM carbonyl
cyanide p-trifluoromethoxyphenylhydrazone (FCCP, a pro-
tonophore) (dissolved in the transport medium containing
0.22% ethanol), respectively, were added to the transport
medium. These studies were performed in parallel with
controls in the presence of the corresponding ethanol con-
centration. Uptake was also measured at medium pH
values of 6.0, 7.4 and 8.4. When the influence of intracellu-
lar pH (pHi) was examined, the uptake was measured in
the presence of 30 mM NH4Cl to elevate pHi [9,10]. To
measure the uptake at acidic pHi, extracellular NH4Cl was
removed after the preincubation with 30 mM NH4Cl, be-
cause intracellular NH3 rapidly diffuses out of the cells,
resulting in the accumulation of protons released from
NH4
+ during NH3 generation in the cells. In the inhibition
study, the uptake was measured after incubation with di-
phenhydramine (30 μM) for 15 sec in the presence of
selected inhibitors (amantadine, quinidine, TEA, serotonin,
MPP+ and choline) at the concentration of 1 mM. Diphen-
hydramine uptake (30 – 500 μM, 15 sec) was measured in
the absence and presence of pyrilamine (150 μM) or oxy-
codone (500 μM). [3H]pyrilamine uptake (6 – 500 μM, 10
sec) was also measured in the absence and presence of di-
phenhydramine (50 μM).
In situ brain perfusion study
Brain perfusion was performed by the same method as
reported previously [9,14]. In brief, each rat was anesthe-
tized and the right carotid artery was catheterized with
polyethylene tubing (SP-10) filled with sodium heparin (100
IU/mL). The perfusate (Krebs-Henseleit buffer, 118 mM
NaCl, 4.7 mM KCl, 25 mM NaHCO3, 1.2 mM KH2PO4,
2.5 mM CaCl2, 1.2 mMMgSO4, 10 mM D-glucose, pH 7.4)
containing diphenhydramine (10 μM) or [3H]pyrilamine
and [14C]inulin (0.9 μM), a brain intravascular marker, was
passed through the catheter at the rate of 4.9 mL/min with
an infusion pump (Harvard Apparatus, South Natick, MA,
USA). After the infusion pump is started, 5.0 sec is required
to fill the external carotid artery cannula [15]. Therefore,
5.0 sec was routinely subtracted from the gross perfusion
time in each experiment, to obtain the uptake time for
which the perfusate was actually within the brain capillaries.
At the end of uptake for 5 – 30 sec, rats were decapitated,
and the right cerebral hemisphere was dissected from the
perfused brain and weighed. The brain samples were stored
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at −20°C until determination of diphenhydramine. The
brain uptake of [3H]pyrilamine (1.1 nM) was also deter-
mined as described above. The radioactivity was measured
using a liquid scintillation counter as described above,
after solubilization of the cerebral hemisphere in Soluene-
350 (PerkinElmer Life and Analytical Sciences, Boston,
MA, USA) at 55°C for 3 h and decolorization by addition
of 0.3 mL of 30% H2O2. The value of the permeability-
surface area product (PSBBB,inf), which represents in vivo
BBB permeability, was calculated after correcting for
remaining intravascular diphenhydramine or [3H]pyrila-
mine, estimated from the apparent brain uptake of [14C]
inulin [9,14].
Determination of diphenhydramine
The collected cells in 0.5% KH2PO4 solution were homoge-
nized by sonication. For brain tissue, the cerebral hemi-
sphere was homogenized in 5 volumes of 0.5% KH2PO4
solution. To the homogenate (300 μL) was added orphena-
drine hydrochloride (50 μM, 6.3 μL) as an internal stand-
ard, as well as 60 μL of saturated K2CO3. After mixing,
samples were extracted with 1.5 mL of hexane-isopropanol
(98:2, v/v) by shaking on a horizontal shaker for 15 min
and then centrifuged for 10 min at 800 g. The upper or-
ganic layer was transferred into a tube containing 300 μL of
0.5% KH2PO4. The tube was shaken for 15 min and centri-
fuged for 10 min at 800 g. The upper organic layer was
aspirated off, then 60 μL of saturated K2CO3 was added to
the lower aqueous phase and the extraction step and back-
extraction step were repeated. The final K2CO3 solution
phase was extracted again with 1.5 mL of hexane-
isopropanol and the extract was dried under a nitrogen
stream. The residue was reconstituted in 100 μL of mobile
phase.
Diphenhydramine was determined by ultra-performance
liquid chromatography (UPLCW) with a UV detector by
modification of previously reported methods [16,17]. A
7.5 μL aliquot was injected into the UPLCW. The UPLCW
system (Waters ACQUITY, Milford, MA, USA) consisted
of a binary solvent manager, sample manager and UV de-
tector. The analytical column used was an ACQUITY
UPLC BEH C18 (2.1 mm × 50 mm, 1.7 μm particle size,
Waters). The UPLC separation was carried out at a flow
rate of 0.15 mL/min with a mobile phase containing 25%
acetonitrile and 0.22 M phosphate buffer. UV detection
was performed at 205 nm. The retention times of diphen-
hydramine and orphenadrine were 6.4 and 9.1 min,
respectively. The detection limit for quantification of di-
phenhydramine was 75 pmol.
Expression profiling of organic cation transporters by
real-time PCR
The mRNA levels of typical organic cation transporters
(hOCT1-3, hOCTN1-2, hMATE1-2, hPMAT) in the
hCMEC/D3 cells were measured by quantitative real-time
PCR analysis. Total RNA was isolated from hCMEC/D3
cells using an RNeasy mini kit (Qiagen, Valencia, CA,
USA). Single-strand cDNA was prepared from 1.0 μg of
total RNA by RT (Superscript III, Invitrogen, Carlsbad,
CA, USA) using random primers. Quantitative real-time
PCR analysis was performed using a 7500 sequence detec-
tion system (PE Applied Biosystems, Foster City, CA,
USA) with 2x SYBR Green PCR Master Mix (PE Applied
Biosystems) according to the manufacturer's protocols.
The primers are listed in Table 1. The thermal protocol
was set to 2 min at 50°C, followed by 10 min at 95°C, and
then 40 cycles of 15 sec at 95°C and 1 min at 60°C. The
relative expression levels of these mRNAs were calculated
using the comparative Ct method for relative quantifica-
tion based on the mRNA level of the housekeeping gene
encoding GAPDH, according to the manufacturer's proto-
cols. The control, lacking the RT enzyme, was assayed in
parallel to monitor genomic contamination. To confirm
specificity of amplification, the PCR products were sub-
jected to melting curve analysis.
Statistical analysis
Statistical analysis of the data was performed by employ-
ing Student’s t-test and by one-way analysis of variance
followed by Dunnett’s test for single and multiple com-
parisons, respectively. Differences were considered sta-
tistically significant at P < 0.05.
Table 1 Sense and antisense primers for quantitative PCR
Target mRNA Sequence(5’-3’) Product size
(Accession number) (bp)
hOCT1/SLC22A1 AATGGACCACATCGCTCAAAA
(NM_003057) CTTCGAGGGAAAGCATCTTTAAAT 68
hOCT2/SLC22A2 GGACGGCTGGGTGTACGA
(NM_003058) GGAGTTGGCACATACCAGGTTAA 70
hOCT3/SLC22A3 CATGCCTTGTCACTGCGTTCT
(NM_021977) ATGTAGCCACTGTGGTCCTCAA 63
hOCTN1/SLC22A4 CCAGAGTGGGCAGCATCAT
(NM_003059) TAGGGCAGCATTCTGTTGTAAGC 67
hOCTN2/SLC22A5 CCTTCTCTTCATGCAGCTGGTA
(NM_003060) CCCACCATCACCAGGACTGT 66
hMATE1/SLC44A1 CAGTCACGCTGGCAATCG
(NM_080546) GGTGTCACAGGCAGAAGATAAGC 77
hMATE2/SLC44A2 TCTGAGAGGAACTGGGAAGCA
(NM_152908) AGGCCGATGATGTAATATGTGATG 69
hPMAT/SLC29A4 CAGCTTTCACGGATACTACATTGG
(NM_001040661) GCAAAGTAGATGGCGTGATAACG 67
hGAPDH CCACATCGCTCAGACACCAT
(NM_002046) GCGCCCAATACGACCAAAT 66
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Results
Uptake kinetics of diphenhydramine and [3H]pyrilamine
by hCMEC/D3 cells
The uptake of diphenhydramine (30 μM) increased in
proportion with time until 60 sec at 37°C, and reached
equilibrium with the cell-to-medium (C/M) ratio of 97.7 –
103 μL/mg protein at 60 – 180 sec (Figure 1A). [3H]Pyrila-
mine uptake (74 kBq/μL, 90 nM) by hCMEC/D3 cells also
increased linearly with time until 30 sec, and the C/M
ratio was 161 – 186 μL/mg protein at 30 – 60 sec
(Figure 2A). Therefore, the initial uptake rate was assessed
at 15 sec for diphenhydramine and 10 sec for [3H]pyrila-
mine, in the subsequent kinetic and inhibition studies.
The initial uptakes of diphenhydramine and [3H]pyrila-
mine were concentration-dependent (Figures 1B and
2B). Eadie-Hofstee plot for diphenhydramine uptake
gave a single straight line (r2 = 0.859), indicating in-
volvement of a single saturable process (Figure 1C).
Although the Eadie-Hofstee plot for [3H]pyrilamine
uptake has the lower r2 value (0.679) than that for di-
phenhydramine, the kinetic parameters for both drugs
were analyzed assuming that each drug has a single
saturable transport process, on the basis of our previous
reports [9,10]. Kinetic analysis provided a Km value of
59 μM and a Vmax of 13 nmol/mg protein/min for di-
phenhydramine, and a Km value of 19 μM and a Vmax of
3.5 nmol/mg protein/min for [3H]pyrilamine. The Vmax/
Km values (uptake clearance) for diphenhydramine and
[3H]pyrilamine were 220 and 184 (μL/min/mg protein),
respectively.
Metabolic energy and ion dependence of the uptake of
diphenhydramine by hCMEC/D3 cells
Diphenhydramine uptake in hCMEC/D3 cells was sig-
nificantly inhibited by pretreatment with rotenone
and sodium azide, but was not affected by replace-
ment of extracellular sodium ion with N-methylgluca-
mine+ or by treatment with valinomycin, a potassium
ionophore (Table 2).
The C/M ratio of diphenhydramine was decreased in
acidic transport medium (pH 6.0) and significantly
increased in alkaline medium (pH 8.4) by 2.1-fold, com-
pared with that at pH 7.4 (Figure 3A); it was also
decreased by treatment with FCCP, a protonophore
(Table 2). To examine the effect of protons as a driving
force, the cells were treated with NH4Cl, because the
intracellular pH (pHi) value rises in the presence of
NH4Cl (acute treatment), whereas pretreatment and
subsequent removal of NH4Cl (pretreatment) causes a
decrease in the pHi value. Intracellular alkalization
markedly reduced diphenhydramine uptake, while intra-
cellular acidification resulted in stimulation of diphen-
hydramine uptake (Figure 3B).
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Figure 1 Diphenhydramine uptake by hCMEC/D3 cells. (A) Time
course of the cell-to-medium (C/M) ratio of diphenhydramine
uptake by hCMEC/D3 cells. Uptake of diphenhydramine (30 μM) was
measured at 37°C. (B) Concentration-dependence of the initial
uptake rate of diphenhydramine in hCMEC/D3 cells. hCMEC/D3 cells
were preincubated with incubation buffer (122 mM NaCl, 3 mM KCl,
25 mM NaHCO3, 1.2 mM MgSO4, 1.4 mM CaCl2, 10 mM D-glucose,
10 mM HEPES, pH 7.4) for 20 min at 37°C. Uptake of
diphenhydramine (30 μM) was measured at 37°C for 15 sec. (C)
Eadie-Hofstee plot of diphenhydramine uptake by hCMEC/D3 cells.
V, initial uptake rate (nmol/mg protein/15 sec). [S], diphenhydramine
concentration in the transport medium (μM). Each point represents
the mean ± S.E. from three to four determinations. When verticals
are not shown, the S.E. is contained within the limits of the symbols.
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Inhibition of uptake of diphenhydramine and [3H]
pyrilamine by hCMEC/D3 cells
In Lineweaver-Burk plot analyses of mutual inhibitory
effects on uptake of diphenhydramine and pyrilamine
(Figure 4), the plots of diphenhydramine uptake in the
presence and absence of pyrilamine intersected at the
ordinate axis (Figure 4A). This result indicated that pyrila-
mine competitively inhibited diphenhydramine uptake with
a Ki value of 240 μM. Diphenhydramine also competitively
inhibited [3H]pyrilamine uptake with a Ki value of 28.9 μM
(Figure 4B). These mutual and competitive inhibitions
between diphenhydramine and pyrilamine suggest that a
common transporter is involved in their influx transport
into the hCMEC/D3 cells, at least in part. Further, diphen-
hydramine uptake was competitively inhibited by oxy-
codone with a Ki value of 304 μM (Figure 4C). In the
inhibition study, diphenhydramine uptake was significantly
inhibited by the cationic compounds amantadine and
quinidine to less than 25% of the control, while TEA
(a classical substrate and/or inhibitor of OCTs), MPP+
(a classical substrate and/or inhibitor of PMAT as well as
OCTs), serotonin, and choline (a substrate or inhibitor of
the choline transport system) had little effect (Table 3).
mRNA expression of organic cation transporters in
hCMEC/D3 cells
To provide molecular evidence for the expression of or-
ganic cation transporters in hCMEC/D3 cells, the mRNA
expression levels of hOCT1, hOCT2, hOCT3, hOCTN1,
hOCTN2, hMATE1, hMATE2 and hPMAT in hCMEC/
D3 cells were determined by quantitative RT-PCR analysis
(Table 4). Relatively high mRNA expression of hOCTN2
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Figure 2 [3H]pyrilamine uptake by hCMEC/D3 cells. (A) Time
course of the cell-to-medium (C/M) ratio of [3H]pyrilamine uptake by
hCMEC/D3 cells. Uptake of [3H]pyrilamine (74 kBq/μL, 90 nM) was
measured at 37°C. (B) Concentration-dependence of the initial
uptake rate of [3H]pyrilamine in hCMEC/D3 cells. hCMEC/D3 cells
were preincubated with incubation buffer (122 mM NaCl, 3 mM KCl,
25 mM NaHCO3, 1.2 mM MgSO4, 1.4 mM CaCl2, 10 mM D-glucose,
10 mM HEPES, pH 7.4) for 20 min at 37°C. Uptake of [3H]pyrilamine
(74 kBq/μL, 90 nM) was measured at 37°C for 10 sec. (C) Eadie-
Hofstee plot of [3H]pyrilamine uptake by hCMEC/D3 cells. V, initial
uptake rate (nmol/mg protein/10 sec). [S], [3H]pyrilamine
concentration in the transport medium (μM). Each point represents
the mean ± S.E. from three to four determinations. When verticals
are not shown, the S.E. is contained within the limits of the symbols.
Table 2 Effects of metabolic inhibitors (rotenone and
sodium azide), protonophore (FCCP), sodium
replacement and change in membrane potential by
valinomycin on diphenhydramine uptake by
hCMEC/D3 cells
Treatment Relative uptake (% of control)
Rotenone (25 μM) a), b) 29.6 ± 26.9 **
Sodium azide (0.1%) b) 11.8 ± 0.4 **
10 μM FCCP 30.6 ± 1.3 ***
Na+ replacement 95.3 ± 4.5
Valinomycin (10 μM) c) 84.1 ± 0.2
Uptake of diphenhydramine (30 μM) was measured at 37°C for 15 sec in the
absence or presence of metabolic inhibitors (25 μM rotenone and 0.1%
sodium azide) and a protonophore (10 μM p- FCCP) and 10 µM valinomycin.
The uptake was also measured in sodium-free incubation buffer (Na+ was
replaced with N-methylglucamine). a) Rotenone was dissolved in the transport
buffer containing 0.25% ethanol. b) 25 µM rotenone and 0.1% sodium azide
were added to the transport buffer without 10 mM D-glucose to reduce
metabolic energy. c) The cells were preincubated with the transport buffer
containing 10 μM valinomycin for 10 min. Valinomycin was dissolved in the
transport buffer containing 0.22% ethanol. Each study was performed in
parallel with a control containing the corresponding ethanol concentration.
Each value represents the mean as % of control ± S.E. (n = 3). **p<0.01 and
**p<0.001 vs control.
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was found, followed by hOCTN1 and hPMAT. In
contrast, little expression of hOCTs and hMATEs mRNAs
was seen in hCMEC/D3 cells.
In vivo blood-to-brain transport of diphenhydramine and
[3H]pyrilamine in rats
The brain uptakes of diphenhydramine and [3H]pyrilamine
were measured by the in situ brain perfusion technique. The
brain/perfusate (B/P) ratios of diphenhydramine and [3H]
pyrilamine linearly increased with increasing perfusion time
up to 30 sec. The PSBBB,inf values for diphenhydramine and
[3H]pyrilamine were 4.40 and 1.30 mL/min/g brain, respect-
ively. The PSBBB,inf value for [
3H]pyrilamine was similar to
the value reported previously (1.6 mL/min/g brain) [18].
Discussion
There is increasing evidence that the immortalized
human brain capillary endothelial cell line hCMEC/D3 is
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Figure 3 Effect of extracellular pH and intracellular pH on
diphenhydramine uptake by hCMEC/D3 cells. (A) Uptake of
diphenhydramine (30 μM) was measured at 37°C for 15 sec at
medium pH values of 6.0, 7.4 and 8.4. Each column represents the
mean ± S.E. of three determinations. Asterisks show a significant
difference, *P<0.05 vs pH 7.4 (control). (B) Uptake of
diphenhydramine (30 μM) was measured at 37°C, pH 7.4 for 15 sec.
The uptake was measured in the presence of 30 mM NH4Cl to
elevate intracellular pH (pHi) (NH4Cl (acute)). To measure the uptake
at acidic pHi, extracellular NH4Cl was removed after preincubation
with 30 mM NH4Cl for 20 min (NH4Cl (pre)). Each column represents
the mean ± S.E. of three determinations. Asterisks show a significant
difference, **P<0.01 vs control.
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Figure 4 Lineweaver-Burk plot of mutual inhibitory effects on
uptakes of diphenhydramine or [3H]pyrilamine by hCMEC/D3
cells. Diphenhydramine uptake was measured at 37°C for 15 sec in
the presence (●) or absence (○) of pyrilamine (150 μM) (A) or
oxycodone (500 μM) (C). [3H]Pyrilamine uptake was also measured
at 37°C for 10 sec in the presence (●) or absence (○) of
diphenhydramine (50 μM) (B). Each point represents the mean ± S.E.
of four determinations.
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a good model to predict BBB permeability in the human
brain [5,19]. In the present study, we further investigated
the utility of this model by examining whether H+/OC
antiporter is functionally expressed in the cells.
Although this putative H+/OC antiporter still remains to
be identified at the molecular level, it is known to trans-
port several CNS-acting drugs with secondary or tertiary
amine moieties, including diphenhydramine, oxycodone,
pyrilamine and clonidine [9,10,12].
Diphenhydramine, pyrilamine and oxycodone each form
a cation at physiological pH because they are weak bases
having a tertiary amine moiety. We previously showed
that diphenhydramine, pyrilamine and oxycodone are
taken up via a pH-sensitive, energy-dependent, proton-
coupled antiport system in TR-BBB13 cells, which are an
in vitro rat BBB model [9,10]. In addition, both diphen-
hydramine and oxycodone have been reported to be
actively taken up by the brain across the BBB with a Kp,
uu (unbound concentration ratio of brain interstitial fluid
to plasma) value of more than 3 in rats [10,11]. Conse-
quently, we have suggested that H+/OC antiporter works
in the rat BBB as an active influx transporter. In the
present study, diphenhydramine and pyrilamine were used
as substrates to investigate this activity.
The uptakes of diphenhydramine and [3H]pyrilamine
were time- and concentration-dependent. Kinetic analyses
revealed that the calculated uptake clearances (Vmax/Km)
for diphenhydramine (220 μL/min/mg protein) and [3H]
pyrilamine (184 μL/min/mg protein) were in good agree-
ment with those of diphenhydramine (440 μL/min/mg
protein) and [3H]pyrilamine (140 μL/min/mg protein) in
conditionally immortalized rat brain capillary endothelial
cells (TR-BBB13) [9,10]. These results suggest that a trans-
porter with similar transport activity and transport clear-
ance to those observed in the case of TR-BBB13 cells is
involved in uptake of diphenhydramine and [3H]pyrila-
mine by hCMEC/D3 cells. Furthermore, the transporter
seems to show no marked species difference between
TR-BBB13 cells and hCMEC/D3 cells.
The uptake of diphenhydramine was significantly inhib-
ited by pretreatment with metabolic inhibitors, but was in-
sensitive to extracellular sodium and membrane potential
in hCMEC/D3 cells (Table 2), suggesting the involvement
of a transporter having similar energy and membrane po-
tential dependencies to those of TR-BBB13 cells. Further-
more, the diphenhydramine uptake by hCMEC/D3 cells
showed pH-dependency characteristic of a proton-coupled
antiporter. The uptake was increased at higher extracellular
pH (pH 8.4), and decreased in the presence of FCCP. Intra-
cellular acidification induced with NH4Cl, stimulated the
uptake (Figure 3 and Table 2). As the pKa value of diphen-
hydramine is 8.98, the proportion of uncharged diphen-
hydramine can be estimated to be 20.8% at pH 8.4, 2.6% at
pH 7.4 and 0.1% at pH 6.0. Compared to the large change
of the uncharged fraction (one twenty-sixth at pH 6.0 and
eightfold at pH 8.4 compared with pH 7.4), the acidifica-
tion (pH 6.0) or alkalization (pH 8.4) caused a small change
in diphenhydramine uptake (two-fifths at pH6.0 and two-
fold at pH 8.4 of control uptake at pH7.4), suggesting that
passive diffusion according to the pH-partition theory
could not be solely responsible for diphenhydramine up-
take by hCMEC/D3 cells. This view is further supported by
the result that an outward proton gradient from intracellu-
lar fluid to extracellular medium effectively enhanced
diphenhydramine uptake by hCMEC/D3 cells.
The results of the inhibition study (Figure 4 and
Table 3) also indicate that H+/OC antiporter is function-
ally expressed in hCMEC/D3 cells. Diphenhydramine
and pyrilamine each mutually inhibited the uptake of the
other, suggesting the occurrence of competition between
oxycodone and pyrilamine for a common transporter.
Oxycodone also competitively inhibited diphenhydramine
transport in hCMEC/D3 cells (Figure 4). A variety of
organic cations with widely differing molecular structures
(type II cations), such as pyrilamine, oxycodone, quinidine
and amantadine, markedly inhibited diphenhydramine
Table 3 Inhibitory effects of various compounds on
diphenhydramine uptake by hCMEC/D3 cells
Inhibitor Concentration (mM) Relative uptake (% of control)
Amantadine 1 23.7 ± 3.8 ***
Quinidine 1 24.0 ± 6.2 ***
TEA 1 98.9 ± 12.3
Serotonin 1 84.7 ± 14.9
MPP+ 1 90.2 ± 11.4
Choline 1 74.1 ± 7.3
The inhibitory effects of selected compounds on diphenhydramine uptake by
hCMEC/D3 cells. Uptake of diphenhydramine (30 μM) was measured at 37°C
for 15 sec in the transport medium (pH 7.4) containing each compound
(1 mM). Each column represents mean ± S.E. of three determinations.
Asterisks show a significant difference, *** P < 0.01 vs control.
Table 4 mRNA expression levels of organic cation
transporters in hCMEC/D3cells determined by
quantitative RT-PCR analysis
Target mRNA mRNA expression
(target mRNA x 105/GAPDH mRNA)
hOCT1/SLC22A1 1.99 ± 0.21
hOCT2/SLC22A2 N. D.
hOCT3/SLC22A3 8.59 ± 0.55
hOCTN1/SLC22A4 80.7 ± 4.6
hOCTN2/SLC22A5 248 ± 7.3
hMATE1/SLC44A1 0.29 ± 0.02
hMATE2/SLC44A2 1.15 ± 0.16
hPMAT/SLC29A4 34.0 ± 2.4
Each value represents the mean ± S.E. of eight determinations. N.D.:
not detected.
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uptake by hCMEC/D3 cells (Figure 4 and Table 3). These
results are consistent with those obtained in TR-BBB13
cells [9,10,20]. In contrast, TEA and serotonin, which are
prototypical substrates/inhibitors of OCT1-3 and PMAT,
respectively, had no significant effect. Given that the trans-
port activities of OCT1-3 and PMAT are reduced by mem-
brane depolarization, it is unlikely that these cation
transporters are the molecular entity of the H+/OC antipor-
ter. Low or negligible expression of hOCT1-2 mRNA in
hCMEC/D3 cells also supports this idea (Table 4).
Quantitative RT-PCR analysis showed that the expres-
sion level of hOCTN2 was the highest in hCMEC/D3
cells, followed by hOCTN1, hPMAT, hOCT3 and hOCT1.
On the other hand, the expression levels of hOCT2 and
hMATE1-2 were negligible or low in hCMEC/D3 cells.
Expression levels of these mRNAs in hCMEC/D3 cells
were similar to those reported in TR-BBB13 cells [9] and
rat brain capillary endothelial cells (RBEC1) [21]. The
H+/OC antiporter at the BBB remains molecularly
unidentified even in rodents. Because hCMEC/D3 cells
possess a H+/OC antiporter, like rodent BBB, and show
similar mRNA expression of identified organic cation
transporters to those in rat BBB model cells, hCMEC/D3
cells should be a good in vitro model for further studies
on the H+/OC antiporter. Kooijmans et al. have reported
that amino acid transporter B0,+ (SLC6A14) is involved in
Na+- and Cl--dependent amantadine transport in hCMEC/
D3 cells [22]. Although amantadine inhibited diphenhydra-
mine transport in hCMEC/D3 cells, diphenhydramine
transport was insensitive to extracellular Na+. Thus, an
unidentified transport system different from SLC6A14
seems to be a candidate for the H+/OC antiporter.
An aim of this study was to investigate whether or not
the results of in vitro uptake study using hCMEC/D3
cells can be extrapolated to the human BBB. As a first
step, the influx BBB permeability-surface area product
(PSBBB,inf ) for diphenhydramine and [
3H]pyrilamine in
rats were compared with those measured by the in vitro
uptake study using TR-BBB13 cells. The value of PSBBB,
inf measured by the in situ brain perfusion is mainly
reflected in the unidirectional clearance from perfusate to
brain across the BBB, as far as the BBB transport process
is the rate-limiting step [15]. The values of PSBBB,inf was
estimated to be 44 and 13 μL/min/cm2 for diphenhydra-
mine and [3H]pyrilamine, respectively, assuming that the
rat brain capillary surface area is 100 cm2/g of brain [3].
These values approximate to the in vitro uptake clearances
in TR-BBB13 cells for diphenhydramine (21 μL/min/cm2)
[10] and [3H]pyrilamine (6.3 μL/min/cm2) [9]. These
results indicate the possibility that the in vivo BBB perme-
ability can be roughly predicted from the in vitro uptake
clearance estimated by BBB model cells, as far as diphen-
hydramine and pyrilamine. In hCMEC/D3 cells, in vitro
uptake clearance for [3H]pyrilamine is estimated to be 8.39
μL/min/cm2, which is in fairly good agreement with the
in vivo human BBB of [11C]pyrilamine (15 μL/min/cm2)
estimated from a positron emission tomography (PET)
study [23]. Extensive further studies and human data
will be needed to allow reliable prediction of human
BBB permeability from in vitro uptake studies using
hCMEC/D3 cells.
Conclusion
Our results strongly suggest that H+/OC antiporter is
functionally expressed in the immortalized human brain
capillary endothelial cell line hCMEC/D3. Like the
putative H+/OC antiporter in rodents, the transporter
was energy-dependent and also dependent on an oppos-
itely directed proton gradient, but was sodium ion- or
membrane potential-independent. These findings should
be relevant to the development and clinical application
of CNS-acting cationic drugs in humans. We suggest
that the hCMEC/D3 cell line should be a useful model
system in the development of new CNS-acting drugs
and optimal pharmacotherapy for various CNS diseases.
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